The Possible Effects of Roflumilast on Obesity Related Disorders
Primary Purpose
Obesity, PreDiabetes
Status
Completed
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Roflumilast
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- Prediabetic patients (fasting blood glucose between 100 mg/dl and 125 mg/dl or HbA1C within the range 5.7% and 6.4%).
- Obese subjects (BMI ≥30 kg/m2 and <40 kg/m2).
Exclusion Criteria:
- Patients with morbid obesity (BMI > 40 kg/m2).
- Patients already on weight lowering agents or weight loss program.
- History or current diagnosis of major depressive disorder or other psychiatric disorders that in the opinion of the investigator would make participation unsafe for the participant.
- Moderate to severe liver disease (Child-Pugh B or C), renal disease, thyroid disease, cardiovascular disease, peripheral vascular disease or coagulopathy.
- Women will be excluded from our study if they are pregnant, breastfeeding, currently on contraceptive pills or if they plan to become pregnant prior to the end of the study.
- Patients on medications that can interfere with glucose or lipid metabolism (e.g. hypoglycemic agents, corticosteroids, anti-hyperlipidemics, non-selective β-blockers thiazides, etc.) and subjects with organic causes of obesity.
- Diabetic patients and patients with any inflammatory disease.
- Smokers.
- Patients on cytochrome P450 inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin, etc.)
Sites / Locations
- Sara Mohammad Zayed
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Roflumilast arm
Placebo arm
Arm Description
Outcomes
Primary Outcome Measures
Change in patients body weight
substracting pre-treatment from post-treatment values.
Change in blood glucose
using glucose oxidase method for assessment of blood glucose and substracting pre-treatment from post-treatment values.
Change in plasma insulin level
substracting pre-treatment from post-treatment values of plasma insulin.
Change in HOMA-IR index
HOMA-IR will be calculated for all patients at baseline and 3 months later.
Change in blood lipid levels
blood lipid levels will be measured at baseline and 3 months after treatment including total cholesterol, triglycerides, HDL-C and LDL-C.
Secondary Outcome Measures
Changes in TNF-alfa serum level
substracting pre-treatment from post-treatment values of TNF-alfa.
Changes in malondialdehyde serum level (MDA)
substracting pre-treatment from post-treatment values of MDA.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04800172
Brief Title
The Possible Effects of Roflumilast on Obesity Related Disorders
Official Title
The Possible Effects of Roflumilast on Obesity Related Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
May 1, 2021 (Actual)
Primary Completion Date
March 31, 2022 (Actual)
Study Completion Date
March 31, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tanta University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
Evaluation of the possible effects of roflumilast on weight, glucose and lipid metabolism, insulin resistance, oxidative stress and inflammatory process in prediabetic obese subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, PreDiabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
double-blind
Allocation
Randomized
Enrollment
66 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Roflumilast arm
Arm Type
Active Comparator
Arm Title
Placebo arm
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Roflumilast
Intervention Description
administration of roflumilast 500 mcg tablet once daily for 3 months.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
administration of placebo tablet once daily for 3 months.
Primary Outcome Measure Information:
Title
Change in patients body weight
Description
substracting pre-treatment from post-treatment values.
Time Frame
baseline and 3 months later
Title
Change in blood glucose
Description
using glucose oxidase method for assessment of blood glucose and substracting pre-treatment from post-treatment values.
Time Frame
baseline and 3 months later
Title
Change in plasma insulin level
Description
substracting pre-treatment from post-treatment values of plasma insulin.
Time Frame
baseline and 3 months later
Title
Change in HOMA-IR index
Description
HOMA-IR will be calculated for all patients at baseline and 3 months later.
Time Frame
baseline and 3 months later
Title
Change in blood lipid levels
Description
blood lipid levels will be measured at baseline and 3 months after treatment including total cholesterol, triglycerides, HDL-C and LDL-C.
Time Frame
baseline and 3 months later
Secondary Outcome Measure Information:
Title
Changes in TNF-alfa serum level
Description
substracting pre-treatment from post-treatment values of TNF-alfa.
Time Frame
baseline and 3 months later
Title
Changes in malondialdehyde serum level (MDA)
Description
substracting pre-treatment from post-treatment values of MDA.
Time Frame
baseline and 3 months later
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Prediabetic patients (fasting blood glucose between 100 mg/dl and 125 mg/dl or HbA1C within the range 5.7% and 6.4%).
Obese subjects (BMI ≥30 kg/m2 and <40 kg/m2).
Exclusion Criteria:
Patients with morbid obesity (BMI > 40 kg/m2).
Patients already on weight lowering agents or weight loss program.
History or current diagnosis of major depressive disorder or other psychiatric disorders that in the opinion of the investigator would make participation unsafe for the participant.
Moderate to severe liver disease (Child-Pugh B or C), renal disease, thyroid disease, cardiovascular disease, peripheral vascular disease or coagulopathy.
Women will be excluded from our study if they are pregnant, breastfeeding, currently on contraceptive pills or if they plan to become pregnant prior to the end of the study.
Patients on medications that can interfere with glucose or lipid metabolism (e.g. hypoglycemic agents, corticosteroids, anti-hyperlipidemics, non-selective β-blockers thiazides, etc.) and subjects with organic causes of obesity.
Diabetic patients and patients with any inflammatory disease.
Smokers.
Patients on cytochrome P450 inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin, etc.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara M Zayed
Organizational Affiliation
Tanta University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sara Mohammad Zayed
City
Tanta
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Data of outcomes and other research but not personal data are intended to be published in application to scientific journals
Learn more about this trial
The Possible Effects of Roflumilast on Obesity Related Disorders
We'll reach out to this number within 24 hrs